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Abstract  
Background: Nutritional risk index (NRI) has been shown to better predict survival 
than body mass index (BMI) or albumin after several cardiovascular interventions. 
Under assessment herein is whether NRI can have higher predictive value than 
conventional parameters for short-term survival after transcatheter aortic valve 
replacement (TAVR). 
Methods: A prospective cohort study was performed. In-hospital, 1-month and 3-month 
survival was evaluated. Since most patients undergoing TAVR are over 65, the NRI 
definition for a geriatric population (GNRI) was used. The impact of baseline BMI, 
albumin levels, and GNRI on in-hospital and short-term survival was assessed. 
Results: 152 patients aged 82 ± 5.4 were included. In-hospital, 1-month, and 3-month 
mortality was 5.3%, 5.9%, and 9.2%, respectively. Mean GNRI was 112.7 ± 11.9, and 
was significantly lower in patients who died in-hospital (101.0 ± 8.8 vs. 113.3 ± 11.7), 
at 30 days (103.4 ± 10.9 vs. 113.3 ± 11.7), and at 90 days (104.0 ± 9.6 vs. 113.6 ± 11.8) 
than in survivors (all, p < 0.05). Three-month mortality in patients with no nutritional 
risk was 6.8% (9/132) vs. 25% (5/20) in patients with malnutrition (p = 0.022). In 
univariate analysis, GNRI predicted in-hospital, 30-day, and 90-day mortality (all, p < 
0.05). Predictive value remained significant after adjusting for age, EuroSCORE II, and 
STS-Score (p < 0.05). Based on Receiver operating curves, GNRI (AUC: 0.73) showed 
a better discrimination for 3-month mortality than albumin (0.69), weight (0.67) or BMI 
(0.62). The optimal cut-off value was 109.8.  
Conclusions: The geriatric nutritional risk index predicts short-term mortality after 
TAVR and has a higher discriminating ability than other commonly used nutritional 
variables. It is a simple parameter that identifies those patients who could benefit from 
pre-procedural nutritional therapy.  
Key words: aortic valve stenosis, body mass index, transcatheter aortic valve 
replacement, hypoalbuminemia 
 
 
Introduction 
Malnutrition is frequent in elderly patients and has been shown to affect survival 
in several cardiovascular diseases, such as chronic heart failure [1] or coronary artery 
disease [2]. Transcatheter aortic valve replacement (TAVR) is mainly performed in 
high-risk patients, the vast majority of which are geriatric patients. In such patients, 
nutritional status could be a useful prognostic factor to be considered before any 
planned TAVR. Nutritional status in patients undergoing TAVR has been evaluated in 
several ways, including body mass index (BMI) and laboratory parameters such as 
albumin levels. Higher BMI and higher albumin levels have been previously associated 
with more favorable outcomes after TAVR [3]. Regarding albumin, low baseline levels 
have been shown to predict in-hospital, 30-day and long-term mortality [3, 4]. 
Furthermore, a meta-analysis has shown BMI, as a continuous variable, to be associated 
with a better early prognosis after TAVR [5]. The nutritional risk index (NRI), 
originally described by Buzby et al. [6], is a simple tool that combines both clinical and 
laboratory parameters. Since its introduction, it has been applied in several medical 
specialties, mainly in the field of oncology [7, 8]. NRI has been recently shown to have 
a better prognostic value than both BMI and albumin in several cardiovascular diseases 
and procedures, including acute or chronic heart failure [1, 9], heart transplants [10], 
coronary artery disease [2] or percutaneous coronary interventions [11]. NRI is not only 
an easy tool to assess nutritional status, but it does not require any complex or 
additional test to those performed routinely on admission. The geriatric nutritional risk 
index (GNRI) is a version of the NRI adapted for elderly patients; thus, it could be 
particularly useful for the population usually undergoing TAVR. The present study 
sought to elucidate the impact of nutritional status, measured with both GNRI and 
conventional parameters, on clinical outcomes and particularly short-term survival after 
TAVR. 
 
Methods 
Study population 
A prospective, observational, cohort study was performed in patients undergoing 
TAVR with a new generation valve prosthesis using a transfemoral access from July 
2016 to September 2017 in the documented center. Consecutive patients with 
symptomatic severe aortic stenosis having a prohibiting risk for surgical aortic valve 
replacement were included, as assessed by a multidisciplinary Heart Team. Patients 
with an isolated or combined severe aortic regurgitation and patients requiring a valve-
in-valve procedure were also included. 
 
Procedures 
Pre-procedural baseline demographic, clinical and laboratory characteristics 
were assessed and baseline nutritional data, including serum albumin and BMI, were 
obtained. New York Health Association (NYHA) class was assessed, and EuroSCORE 
II and STS scores were documented. 
After a Heart Team decision, TAVR procedures were carried out according to 
standard techniques. The choice of prosthesis was left to operator discretion. Use of 
local anesthesia and conscious sedation was the aim for all patients. Procedural details 
were also recorded. 
In-hospital survival was evaluated and at follow-up to assess vital status, which 
was performed at 1 and 3 months through outpatient visits and/or with telephone 
interviews by a physician.  
 
Nutritional assessment based on GNRI 
Since most patients undergoing TAVR are older than 65 the NRI definition 
adapted to an old population was used, as described by Bouillanne et al. [12]: Geriatric 
(G) NRI = (1.489) × Albumin (g/L) + [(41.7 × (present weight/ideal weight)].  
In order to be consistent with GNRI use, patients under 65 years were excluded 
from the analysis. Ideal weight (WLo) was calculated according to Lorentz equations 
[12]:  
WLo (kg) in men: (Height – 100) – [(Height – 150)/4] 
WLo (kg) in women: (Height – 100) – [(Height – 150)/2.5] 
Based on this definition, patients were divided into four grades of nutrition-
related risk, as suggested in the literature [12]: GNRI > 98 (no risk), GNRI 92 to ≤ 98 
(low risk), GNRI 82 to < 92, (moderate risk), and GNRI < 82 (major risk). Due to the 
low number of malnourished individuals, for inferential categorical analyses, all 
patients with some degree of malnutrition were combined into one category (GNRI  
98) and those without malnutrition into another one (GNRI > 98).  
 
Outcomes 
The primary endpoint of this study was overall mortality at 3 months. Secondary 
endpoints included in-hospital and 1-month mortality. Exploratory variables were 
length of stay in hospital, and NYHA improvement at 3 months after TAVR. 
 
Statistical analysis 
Categorical variables were described with frequencies and percentages, and 
continuous variables were reported with mean ± standard deviation (SD) if normally 
distributed or median (range) if not normally distributed. The Fisher test or chi-square 
was used to compare categorical variables. The Student t-test was used to compare 
means and the Mann-Whitney U test was used to compare medians. Primary and 
secondary endpoints were assessed hierarchically in the following pre-specified order: 
3-month, 1-month, and in-hospital mortality. All other endpoints were considered 
exploratory, and no adjustments were made for multiplicity of tests. Survival prediction 
was evaluated by means of a logistic regression (adjusted by potential confounding 
factors). Statistical significance was based on a p-value < 0.05. Receiver operating 
curves were created to assess sensitivity and specificity of the GNRI in predicting 
survival, as well as those for individual components of the index. The best cut-off value 
was decided using the highest value of the Youden index. SPSS statistical software 
package version 24.0 was used for all analyses. 
All patients gave signed and informed consent prior to intervention and the 
study was performed under the protocol, which was approved by the local ethics 
committee (296/16). 
 
Results 
Study population 
Out of 171 patients who underwent TAVR between July 2016 and September 
2017, 8 patients were excluded from the analysis due to unavailable baseline albumin 
levels and 4 patients were excluded due to missing follow-up data. In order to be 
consistent with GNRI use, 7 patients under 65 years were excluded from the analysis. A 
flow-chart of patient exclusion in the present study population is shown in Figure 1.  
 
Baseline and procedural characteristics 
TAVR was performed in 152 patients using various new generation prostheses 
including Portico valve (St. Jude Medical) (n = 91), Sapien 3 valve (Edwards 
Lifesciences) (n = 20), Evolut R valve (Medtronic) (n = 20), and Symetis valve (Boston 
Scientific) (n = 21).  
Overall mean (± SD) age was 82 ± 5.4 years, and 41.4% of patients were female. 
EuroSCORE II and STS score were 5.3 ± 6 and 4.0 ± 2.8, respectively.   
Baseline and procedural characteristics of the whole population and in patients 
with and without malnutrition are shown in Table 1. Most patients had hypertension 
(93%), and other common comorbidities were coronary artery disease (58%), diabetes 
(35%), and most patients had some degree of chronic renal failure. No significant 
differences were shown between groups except regarding nutritional parameters, 
including weight, albumin and GNRI. Both EuroSCORE II and STS scores differed 
significantly between groups as expected.   
 
Nutritional results 
Overall baseline mean GNRI value was 112.7 ± 11.9, median BMI was 26.9 
(16.4–41.7) kg/m2, and median albumin level was 4.2 (2.5–5) g/dL. Based on GNRI 
values, 86.8% of patients had no nutritional risk (GNRI > 98), 9.9% had low risk (GNRI 
92 to ≤ 98), 3.3% had moderate risk (GNRI 82 to < 92), and no patients were at major 
risk (GNRI < 82) prior to intervention, with median GNRI values being 115.6 ± 9.8, 
95.3 ± 1.8, and 88.1 ± 1.8, respectively. Mean BMI and albumin values varied within 
categories but did not show a clear tendency.  
Mean age was 81.6 ± 5.4 years in no risk patients, 83.7 ± 4.1 years in low risk 
patients, and 86.2 ± 6.9 years in patients at moderate risk. Lower GNRI values (thus, 
more severe malnutrition) were associated with older age; however, this did not reach 
statistical significance. 
 
Clinical outcomes and survival 
Overall mortality was 5.3% in-hospital, 5.9% at 1 month, and 9.2% at 3 month 
follow up. Causes of 3-month mortality were the following: cardiovascular (3 refractory 
cardiogenic shock, and 1 electromechanical dissociation), non-cardiovascular (4 life-
threatening bleeding, 1 life-threatening cerebrovascular accident, 1 critical limb 
ischemia, 1 acute kidney failure, 2 multi-organ failure syndrome), and 1 unknown 
cause. 
Three-month mortality in patients with no nutritional risk was 6.8% (9/132) vs. 
25% (5/20) in patients with some degree of malnutrition according to GNRI (p = 0.022, 
the Fisher test). Mortality at 1-month and in-hospital also showed a similar trend: 4.5% 
(6/132) in well-nourished patients vs. 15% (3/20) in malnourished patients at 1 month, 
and 3.8% (5/132) in well-nourished patients vs. 15% (3/20) in malnourished patients in-
hospital, with differences not reaching statistical significance. 
Mean GNRI values were significantly lower in patients who died in-hospital 
(101.0 ± 8.8 vs. 113.3 ± 11.7), at 30 days (103.4 ± 10.9 vs. 113.3 ± 11.7), and at 90 days 
(104.0 ± 9.6 vs. 113.6 ± 11.8) than in those who survived (two-sample Student t-test, 
all, p < 0.05). Results were also significant for baseline albumin levels when comparing 
patients who died within 3 months after the intervention vs. those who survived: 3.7 
(2.5–4.8) vs. 4.2 (2.7–5) (p = 0.018, Mann-Whitney U Test), respectively. BMI showed 
a numerical difference but did not reach statistical significance. Further details are 
shown in Table 2. 
In univariate analysis, GNRI significantly predicted in-hospital, 30-day and 90-
day mortality (all, p < 0.05). Predictive capacity of GNRI remained significant in 
multivariate analysis after adjusting for potential confounders including age, and pre-
interventional risk-scores (EuroSCORE II and STS-Score) (p < 0.05, logistic 
regression). No other baseline characteristics were significant independent predictors in 
univariate analysis. Albumin level was also significantly predictive, and BMI was 
numerically higher in patients who survived.  
In order to investigate if the predictive value of GNRI was mainly driven by 
results in patients with high vs. low general clinical risk, some post hoc exploratory 
analyses in subgroups of patients were performed as defined by EuroSCORE/STS risk 
level. The overall trend was confirmed in all subgroups. In patients with an 
intermediate/high EuroSCORE II risk (n = 55), mortality rates were 2.44% in patients 
with no nutritional risk vs. 21.43% in patients with some degree of nutritional risk (p < 
0.05). In patients with a low EuroSCORE II risk (n = 97), mortality rates were 8.80% 
vs. 33.30%, respectively (p = 0.11). In patients with an intermediate/high STS risk (n = 
54), mortality rates were 8.80% in patients with no nutritional risk vs. 33.30% in 
patients with some degree of nutritional risk (p = 0.34). In patients with a low STS risk 
(n = 98), mortality rates were 9.76% vs. 23.08%, respectively (p = 0,08). In regression 
analyses the GNRI predictive capacity reached significance in the STS 
high/intermediate group (p < 0.05) and the EuroSCORE low-risk group (p = 0.01). 
According to receiver operating curve (ROC), GNRI showed a better 
discrimination for 3-month mortality than its individual components (3-month: area 
under curve [AUC GNRI: 0.73 vs. AUC albumin: 0.69 vs. AUC weight: 0.67) or BMI 
(AUC BMI: 0.62). Similar results were found for in-hospital and 1-month mortality. 
Receiver operating curve for GNRI and 3-month mortality is shown in Figure 2. The 
optimal GNRI cut-off in the present series was 109.8. 
In a subgroup analysis based on the traditional BMI classification, patients with 
underweight (BMI < 20 kg/m2) showed a numerically higher mortality than normal 
weight, overweight, and obese patients, with the difference not reaching statistical 
significance. Detailed mortality percentages are shown in Figure 3. 
The NYHA class change at three months after TAVR could be assessed in 118 
patients. An improvement of at least one level was shown in most of them (84.7%). 
Such an improvement was observed in 86.6% of patients with no nutrition risk vs. 
69.2% of patients with some degree of nutritional risk (p = NS). 
No significant differences in median length of stay in hospital were observed 
between different nutritional status groups (9 days in patients with no degree of 
malnutrition vs. 10 days in patients with some degree of malnutrition).  
 
Discussion 
Overall outcomes in the current TAVR population are in line with those 
previously described in the literature, with short-term mortality and in-hospital 
complications according to VARC-2 criteria being similar to those reported for all new 
generation valves [13–15]. 
According to available research, this is the first prospective cohort study on the 
predictive value of GNRI in TAVR patients in a European population, in which an 
improved predictive value of GNRI as compared to commonly used nutritional 
parameters is shown and a practical clinical threshold is estimated. Differences between 
patients who died and survivors at 90 days were significant regarding GNRI, weight and 
albumin, but not regarding BMI. The overall GNRI predictive value is supported by the 
uniform trend observed in exploratory analyses in all risk level subgroups defined by 
EuroSCORE and STS scores. Specifically, the significant predictive value of GNRI in 
some subgroups suggests a potential added value of GNRI to predict futility of TAVR. 
GNRI showed a higher discrimination in prediction of short-term mortality than 
its individual parameters or BMI, as shown by ROC-curves. A preliminary GNRI cut-
off value of 109.8 is suggested; further studies in larger populations are warranted to 
confirm its clinical value. The trend to a less common NYHA improvement in patients 
with some degree of nutritional risk is consistent with the overall negative impact of 
poor nutrition on clinical outcomes.  
 Data analysis has recently appeared from a Japanese registry which has also 
suggested that GNRI has a prognostic value in TAVR [16]. Patient details were based 
on registry records and information on deaths were obtained from the treating hospital 
or by calling family members. Although no comparison of its predictive value with 
other nutritional markers were reported, a significantly increased mortality rate was also 
found in patients with lower GNRI values. 
In the present cohort, no patients with a very high-risk malnutrition were 
identified, but several showed some extent of malnutrition. A possible explanation is 
that patients with severe malnutrition or are frail may have been excluded for TAVR 
screening due to the presumed futility of intervention. 
The present results are in line with previously published studies showing a good 
predictive value of pre-operative GNRI in other cardiovascular therapies such as heart 
failure [17], heart transplant [10] or more recently percutaneous coronary intervention 
[11]. Other reports have shown low GNRI to delay rehabilitation after cardiac surgery in 
elderly patients [18], which remains to be studied after TAVR.  
Several studies have shown that low levels of pre-procedural albumin are 
associated with short-term and mid-term mortality [3, 4, 19]. These results have been 
confirmed in the present study. However, the GNRI (combining both albumin and other 
body mass parameters) showed an even better discrimination capacity in predicting 
short-term mortality after TAVR than pre-procedural albumin. 
Body mass index as a continuous variable has previously been shown to be 
associated with a better short-term prognosis after TAVR [5]. Continuous BMI data in 
the current study did not significantly predict mortality, probably due to the low number 
of events. However, median BMI was lower in patients not surviving at 3 months. 
When categorizing patients according to BMI values, underweight patients (BMI < 20 
kg/m2) showed a numerically higher mortality (40%) than all groups with a higher BMI 
(7.1–10%), with the difference not reaching statistical significance. However, this 
association has been significant in other studies with a long-term follow-up [20].  
The interpretation of BMI as a risk factor suggesting malnutrition in patients 
undergoing TAVR is complicated by the so-called “obesity paradox” resulting in a 
better survival in several cardiovascular interventions including TAVR [21, 22]. 
Previous studies have shown that overweight and obese patients undergoing TAVR 
show better outcomes than those with a low BMI [23]. A recent meta-analysis showed 
better short- and long-term survival in obese patients (BMI > 30 kg/m2) compared to 
patients of normal weight [20]. The finding of GNRI being better than BMI and 
albumin in predicting in-hospital/short-term survival in TAVR, even after adjusting for 
potential confounders, could reflect an immediate negative effect of malnutrition rather 
than a favorable effect of overweight/obesity. 
Several nutritional tools have been used in TAVR to assess nutritional status 
such as grip strength, gait speed, bioimpedance analysis, or nutritional questionnaires 
(e.g. Mini Nutritional Assessment [MNA]) [24, 25]. The main limitation of GNRI is 
that it is mainly based on albumin, a biochemical marker that can be affected by other 
co-morbidities, such as hepatic cirrhosis; moreover, inflammatory disorders are known 
to result in a catabolic state and a reduced liver synthesis of albumin. The major 
strength of GNRI is that it is practical, since it only involves one calculation including 
the routinely measured BMI and albumin levels on admission, and no extra equipment 
or measuring devices are required. The need for a formula to estimate GNRI could 
certainly be a practical drawback. However, an online calculator is available at 
http://touchcalc.com/calculators/gnri. Routine recording of pre-interventional GNRI is 
not only easy to perform, but it provides a useful nutritional assessment tool to identify 
those patients at risk of malnutrition. GNRI is suggested to be helpful to classify 
patients regarding their short-term mortality risk. This might help to decide which 
patients could benefit from a nutritional intervention prior to TAVR.  
Malnutrition is frequent in elderly patients undergoing TAVR and it should not 
be overlooked when stratifying patients. Therefore, measuring baseline GNRI values 
and assessing the improvement of such index prior to TAVR could be useful in 
protecting this vulnerable group of patients. As already proven in other heart diseases 
(e.g. heart failure) [26], GNRI is a modifiable factor, both in terms of pre-interventional 
albumin levels and pre-interventional BMI (i.e. weight), and a strategy to improve 
nutritional status before an intervention such as TAVR should be considered. Further 
randomized trials are warranted to test this hypothesis, and to assess the practicality and 
time needed to improve nutritional status in such patients.  
Previous studies in TAVR have shown that some parameters besides the 
conventional risk scores (EuroSCORE II and STS score) offer prognostic information; 
that is diabetes mellitus, mobility and nutritional status measured with questionnaires 
[25]. Other studies have suggested adding baseline albumin levels to risk stratification 
factors before TAVR [4, 27]. If the present results are confirmed by further studies, 
GNRI could be considered in risk scores, it has a stronger prognostic discriminating 
ability than the nutritional parameters already included in such scores and other specific 
measurements such as albumin. 
Being a single-center investigation with a limited sample size are limitations in 
the present study; however, the results are consistent and strongly significant. Some 
other limitations must also be acknowledged. Firstly, as in any observational study, 
although an adjustment was used for the imbalance in major baseline characteristics, 
confounding factors due to unmeasured variables cannot be excluded. Secondly, this is 
the first study from a single center; further studies will be needed at a multicenter level 
for these findings to be extrapolated to a wider population. Thirdly, cause of death was 
not always available because some of the follow-up data on vital status were obtained 
from a family member who was not aware of the exact cause of death. Therefore, data 
on specific causes of death should be interpreted with caution. Fourthly, long-term 
survival was not analyzed in this study; however, GNRI showed a strong association 
with survival in the short-term.  
 
Conclusions 
Geriatric nutritional risk index predicts short-term mortality in patients 
undergoing TAVR and appears to have a higher discriminating ability than other 
commonly used nutritional variables, such as serum albumin and BMI. It is a simple 
and easy to calculate parameter, and its routine use could be useful in identifying those 
patients who could benefit from nutritional therapy prior to intervention. Further 
prospective, multicenter studies with a longer follow-up, as well as randomized trials 
using an established GNRI threshold, and GNRI improvement prior to TAVR are 
needed to confirm this relationship in the long-term. 
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Table 1. Baseline and procedural characteristics of the population according to geriatric 
nutritional risk index (GNRI).  
 Overall 
population (n 
= 152) 
Patients with 
no nutritional 
risk (GNRI > 
98) (n = 132) 
Patients with 
nutritional risk 
(GNRI ≤ 98) 
(n = 20) 
P 
Baseline characteristics 
Age [years] 82 ± 5.4 81.6 ± 5.4 84.4 ± 4.9 0.032 
Sex (female) 41.4% (n = 63) 41.7% (n = 55) 40% (n = 8) 0.888 
Weight [kg] 77.0 ± 14.0 79.0 ± 13.6 63.9 ± 8.9 0.0001 
Ideal weight [kg] 62.2 ± 7.4 62.0 ± 7.3 63.4 ± 8.3 0.442 
Height [cm] 167.1 ± 9.6 166.9 ± 9.5 168.7 ± 10.7 0.427 
BMI [kg/m2] 26.9 (16.4–
41.7) 
27.5 (19.5–
41.7) 
21.9 (16.4–31.1) 0.0001 
Albumin [g/dL] 4.2 (2.5–5) 4.2 (2.6–5) 3.5 (2.5–4.4) 0.0001 
GNRI 112.7 ± 11.9 115.6 ± 9.8 93.5 ± 3.6 0.0001 
Frailty  68.4% (n = 
104) 
67.4% (n = 89) 75% (n = 15) 0.611 
Chronic renal failure 96.7% (n = 
147) 
96.2% (n = 
127) 
100% (n = 20) 0.999 
Carotid occlusive disease  18.4% (n = 28) 17.4% (n = 23) 25% (n = 5) 0.535 
Peripheral artery disease  15.1% (n = 23) 15.9% (n = 21) 10% (n = 2) 0.740 
Previous cardiac surgery  13.2% (n = 20) 11.4% (n = 15) 25% (n = 5) 0.146 
Previous MI  10.5% (n = 16) 9.1% (n = 12) 20% (n = 4) 0.230 
Previous stroke  13.8% (n = 21) 13.6 (n = 18) 15% (n = 3) 0.999 
Previous TIA 2% (n = 3) 2.3% (n = 3) 0% (n = 0) 0.999 
Coronary artery disease 57.9% (n = 88) 56.8% (n = 75) 65% (n = 13)  
Porcelain aorta  17.1% (n = 26) 18.9% (n = 25) 5% (n = 1) 0.200 
COPD 15.8% (n = 24) 15.2% (n = 20) 20% (n = 4) 0.525 
Diabetes 34.9% (n = 53) 34.1% (n = 45) 40% (n = 8) 0.621 
Hypertension  92.8% (n = 
141) 
92.4% (n = 
122) 
95% (n = 19) 0.999 
EuroSCORE II 5.4 ± 6.1 4.8 ± 4.8 9.4 ± 10.5 0.002 
STS score 4.1 ± 2.8 3.6 ± 1.8 7.2 ± 5.1 0.0001  
Procedural characteristics 
Type of valve: 
Portico 
Evolut 
Symetis 
Sapien 3 
 
59.9% (n = 91) 
13.2% (n = 20) 
13.8% (n = 21) 
13.2% (n = 20) 
 
59.1% (n = 78) 
12.9% (n = 17) 
13.6% (n = 18) 
14.4% (n = 19) 
 
65% (n = 13) 
15% (n = 3) 
15% (n = 15) 
5% (n = 1) 
 
Contrast dye [mL] (n = 150) 140 (10–550) 150 (10–550) 125 (50–240) 0.249 
Fluoroscopy time [min] (n = 
149) 
18.4 (7.9–230) 18.4 (7.9–230) 18.4 (8.0–47.0) 0.802 
Simultaneous PCI (n = 150) 2.7% (n = 4) 3.1% (n = 4) 0% (n = 0) 0.999 
Bold figures show significant differences; BMI — body mass index; COPD — chronic obstructive 
pulmonary disease; MI — myocardial infarction PCI — percutaneous coronary intervention; TIA — 
transient ischemic attack 
 
 
Table 2. Baseline characteristics of the population according to short-term survival.  
 Patients with survival 
at 3-months (n = 138) 
Patients who died at 3-
months (n = 14) 
P 
Baseline characteristics  
Age [years] 82 ± 5.3 81.8 ± 6.9 0.919 
Sex (female) 39.9% (n = 55) 57.1% (n = 8) 0.259 
Weight [kg] 77.8 ± 13.9 69.14 ± 13.5 0.027 
Ideal weight [kg] 62.4 ± 7.3 60.1 ± 8.3 0.282 
Height [cm] 167.4 ± 9.5 164.5 ± 10.6 0.291 
BMI [kg/m2] 27.2 (18.1–41.7) 25.1 (16.4–37.4) 0.133 
Albumin [g/dL] 4.2 (2.7–5) 3.7 (2.5–4.8) 0.018 
GNRI 113.6 ± 11.8 104 ± 9.6 0.004 
Frailty 66.7% (n = 92) 85.7% (n = 12) 0.227 
Chronic renal failure 96.4% (n = 133) 100% (n = 14) 0.999 
Carotid occlusive disease 18.1% (n = 25) 21.4% (n = 3) 0.723 
Peripheral artery disease 15.9% (n = 22) 7.1% (n = 1) 0.696 
Previous cardiac surgery 14.5% (n = 20) 0% (n = 0) 0.217 
Previous MI 10.1% (n = 14) 14.3% (n = 2) 0.644 
Previous stroke 13.8% (n = 19) 14.3% (n = 2) 0.999 
Previous TIA 1.4% (n = 2) 7.1% (n = 1) 0.253 
Coronary artery disease 60% (n = 80) 57.1% (n = 8)  
Porcelain aorta 18.1% (n = 25) 7.1% (n = 1) 0.466 
COPD 15.2% (n = 21) 21.4% (n = 3) 0.465 
Diabetes 35.5% (n = 49) 28.6% (n = 4) 0.772 
Hypertension 93.5% (n = 129) 85.7% (n = 12) 0.268 
EuroSCORE II 5.5 ± 6.2 4.3 ± 4.5 0.482 
STS score 4.0 ± 2.7 4.6 ± 3.1 0.486 
Procedural characteristics  
Type of valve: 
Portico 
Evolut 
Symetis 
Sapien 3 
 
71.4% 
12.5% 
0% 
16.1% 
 
84.6% 
7.7% 
7.7% 
0% 
 
Contrast dye [mL] (n  =  
150) 
140 (10–550) 185 (110–270) 0.096 
Fluoroscopy time [min] (n  
=  149) 
18.1 (7.9–230) 20.6 (12.7–47) 0.138 
Simultaneous PCI (n  =  
150) 
2.2% (n = 3) 7.7% (n = 1) 0.327 
Bold figures show significant differences; BMI — body mass index; COPD — chronic obstructive 
pulmonary disease; MI — myocardial infarction PCI — percutaneous coronary intervention; TIA — 
transient ischemic attack 
 
Figure 1. Flowchart of the study population; TAVR — transcatheter aortic valve 
replacement. 
 
Figure 2. Receiver operating curve (ROC) for geriatric nutrition risk index (GNRI) and 
3-month mortality; area under the curve (AUC) 0.74; 95% confidence interval 0.60–
0.88; p < 0.005. 
 
Figure 3. Relationship between 3-month mortality and body mass index (BMI) 
classification. 
 
 
 
 



